Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathway

Xianxian Sui,Canjing Zhang,Jianan Zhou,Shengxuan Cao,Chen Xu,Feng Tang,Xiuling Zhi,Bobin Chen,Songmei Wang,Lianhua Yin

DOI: https://doi.org/10.1186/s13046-017-0601-6

2017-09-26

Abstract:BackgroundExtranodal NK/T cell lymphoma (NKTCL) is a highly aggressive non-Hodgkin lymphoma with poor prognosis. Resveratrol (RSV, 3,5,4′-trihydroxystilbene), a natural nontoxic phenolic compound found in the skin of grapes and some other spermatophytes, performs multiple bioactivities, such as antioxidant activity, anti-aging activity, reduction of cardiovascular disease risk and anticarcinogenic effect. Here we report the anti-tumor effect of RSV in NKTCL cell lines SNT-8, SNK-10 and SNT-16.ResultsRSV inhibited NKTCL cell proliferation in a dose- and time-dependent manner and arrested cell cycle at S phase. It induced NKTCL cells apoptosis through mitochondrial pathway, shown as down-regulation of MCl-1 and survivin, up-regulation of Bax and Bad, and activation of caspase-9 and caspase-3. In addition, we found that RSV suppressed the phosphorylation level of AKT and Stat3, and activated DNA damage response (DDR) pathway directly or through up-regulation of Zta of Epstein-Barr virus (EBV). Furthermore, using KU55933 as the inhibitor of pATM, we verified that DDR played an important role in RSV inducing NKTCL apoptosis. RSV also showed synergistic effect on activating DDR pathway in combination with etoposide or ionizing radiation, which resulted in cell proliferation inhibition and apoptosis.ConclusionsOur results provide in vitro evidence that RSV produces anti-tumor effect by activating DDR pathway in an ATM/Chk2/p53 dependent manner. So we suggest that RSV may be worthy for further study as an anti-tumor drug for NKTCL treatment.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the anti - tumor effect of resveratrol (RSV) on extranodal NK/T - cell lymphoma (NKTCL) and its underlying mechanisms. Specifically, the study aims to verify the following hypotheses:

1. **Whether RSV can inhibit the proliferation of NKTCL cells**: Evaluate the effect of RSV on the proliferation of NKTCL cell lines (SNT - 8, SNK - 10, SNT - 16) under different concentrations and treatment times by cell viability assays.
2. **Whether RSV can induce cell cycle arrest in NKTCL cells**: Analyze the changes in the cell cycle after RSV treatment, especially the proportion of S - phase, by flow cytometry.
3. **Whether RSV can induce apoptosis in NKTCL cells**: Detect the apoptosis of cells after RSV treatment by Annexin V/PI staining and flow cytometry, and analyze the expression changes of apoptosis - related proteins (such as Survivin, Mcl - 1, Bax, Bad, caspase - 9, caspase - 3) by Western blot.
4. **Whether RSV exerts its anti - tumor effect by inhibiting the AKT and Stat3 signaling pathways**: Analyze the changes in the phosphorylation levels of AKT and Stat3 after RSV treatment by Western blot, and further verify the relationship between Stat3 phosphorylation and cell proliferation using the JAK2 inhibitor AG490.
5. **Whether RSV induces apoptosis in NKTCL cells by activating the DNA damage response (DDR) pathway**: Detect the expression changes of pATM and γH2A.X after RSV treatment by Western blot and immunofluorescence techniques, and verify the role of DDR in RSV - induced apoptosis using the ATM inhibitor KU55933.
6. **Whether RSV can induce EBV to enter the lytic phase**: Analyze the expression changes of EBV lytic gene Zta and latent gene LMP1 after RSV treatment by real - time quantitative PCR and Western blot.

Overall, this study aims to comprehensively explore the anti - tumor effect of RSV in NKTCL and its molecular mechanisms, providing a scientific basis for the development of new NKTCL treatment strategies in the future.